Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Karyopharm Therapeutics Inc. (KPTI) is a Biotechnology company based in US with a market capitalization of $178.2M. Revenue grew 0.6% year-over-year and free cash flow was negative at -$75.4M. This page tracks KPTI's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 279 employees · IPO Nov 6, 2013
Valuation
Valuation & price
$7.67as of May 17, 2026· -24.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$178.2M
Market cap
0.6%
Revenue growth (YoY)
95.9%
Gross margin
-$75.4M
Free cash flow (USD)
$169.9M
Net debt
34.6%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
6
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-1.24)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 17, 2026Filing
Retention Program Implemented
- 8-K eventMay 28, 2026Filing
Equity Incentive Plan Amendment
- Insider sellMay 15, 2026Filing
Insider Sell $3KMano Michael · EVP, CLO&Secretary · $2.5K
- Insider sellMay 15, 2026Filing
Insider Sell $21KPaulson Richard A. · Director, President and CEO · $20.9K
- Insider sellMay 15, 2026Filing
Insider Sell $504Abate Kristin · Chief Accounting Officer · $503.5
- Insider sellMay 15, 2026Filing
Insider Sell $3KCheng Sohanya Roshan · EVP & Chief Commercial Officer · $3.1K
- Insider sellMay 15, 2026Filing
Insider Sell $4KRangwala Reshma · EVP & Chief Medical Officer · $3.9K
- Insider sellMay 15, 2026Filing
Insider Sell $4KPoulton Stuart · EVP, Chief Development Officer · $3.8K
- 8-K eventMay 14, 2026Filing
Earnings Release
- Quarterly reportMay 14, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Karyopharm Therapeutics Inc.'s market cap?
Karyopharm Therapeutics Inc. (KPTI) has a market capitalization of $178.2M.
What is KPTI's P/E ratio?
A meaningful P/E ratio is not available for KPTI — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
When did Karyopharm Therapeutics Inc. last report earnings?
KPTI last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying KPTI stock?
SEC Form 4 filings show no open-market insider buys at Karyopharm Therapeutics Inc. in the last 90 days (6 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.